Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Akt
    (5)
  • Apoptosis
    (3)
  • Antioxidant
    (1)
  • Autophagy
    (1)
  • COX
    (1)
  • Calcium Channel
    (1)
  • Caspase
    (1)
  • HIF/HIF Prolyl-Hydroxylase
    (1)
  • NF-κB
    (1)
  • Others
    (8)
Filter
Search Result
Results for "

AKT-IN-5

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    18
    TargetMol | Inhibitors_Agonists
  • Compound Libraries
    1
    TargetMol | Compound_Libraries
  • Natural Products
    4
    TargetMol | Natural_Products
  • Recombinant Protein
    1
    TargetMol | Recombinant_Protein
akt-in-5
T616801402608-05-2
AKT-IN-5 (Example 8) is a potent Akt inhibitor, specifically targeting Akt1 and Akt2 with IC50 values of 450 nM and 400 nM, respectively [1].
  • Inquiry Price
6-8 weeks
Size
QTY
PI3K/Akt/mTOR-IN-5
T89102
PI3K Akt mTOR-IN-5 (compound D3), a derivative of Pseudolaric Acid B, exhibits antitumor activity. This compound inhibits excessive proliferation of tumor cells through the PI3K AKT mTOR and STAT3 GPX4 pathways. Additionally, PI3K Akt mTOR-IN-5 effectively suppresses the EDU positive rate, reduces colony formation, and induces apoptosis (apoptosis) by arresting HCT-116 cells in the S and G2 M phases.
  • Inquiry Price
Size
QTY
Glaucocalyxin A
Wangzaozin B, Leukamenin F
T4S049879498-31-0
1. Glaucocalyxin A (Leukamenin F)-SBE-β-CD could be useful with a better solubility and sustained function in drug delivery. 2. Glaucocalyxin A activates caspase-3, decreases BAD phosphorylation, and reduces the expression of X-linked inhibitor of apoptosis protein. 3. Glaucocalyxin A inhibits Akt phosphorylation, suppresses proliferation, and promotes apoptosis in a dose-dependent manner, but not in normal glial cells. 4. Glaucocalyxin A inhibits collagen-stimulated tyrosine phosphorylation of Syk, LAT, and phospholipase Cγ2, the signaling events in collagen receptor GPⅥ pathway. 5. Glaucocalyxin A could potentially be developed as an antiplatelet and antithrombotic agent, can inhibit platelet p-selectin secretion and integrin activation by convulxin, is a GPVI selective ligand.
  • Inquiry Price
Size
QTY
Oroxylin A
Baicalein 6-methyl ether, 6-Methoxybaicalein
T6S1315480-11-5
1. Oroxylin A (Baicalein 6-methyl ether) has various anti-tumor effects including apoptosis, cell cycle arrest, drug-resistant reversion. 2. Oroxylin A possesses abilities of inhibiting the ATRA-induced IL-6 production via modulation of LAP LIP CHOP in leukemia cell lines, which could providing a therapeutic strategy for RAS. 3. Oroxylin A inhibits UCP2s triggers the MPTP opening, and promotes the apoptosis in CaCo-2 cells; uncoupling protein 2 plays a key role in mitochondrial apoptotic pathway. 4. Oroxylin A inhibits N1ICD translocating to the nucleus and binding to epithelial-mesenchymal transition-related transcription factor Snail, thus suppressing the invasion and migration of MCF-7 cells. 5. Oroxylin A improves the sensitivity of K562 ADM cells by increasing apoptosis in leukemic cells and decreasing the expression of CXCR4 and PI3K Akt NF-κB pathway, and probably served as a most promising agent for CML treatment.
  • Inquiry Price
Size
QTY
CAY10404
3-(4-METHYLSULPHONYLPHENYL)-4-PHENYL-5-T
T8656340267-36-9
CAY10404 (3-(4-METHYLSULPHONYLPHENYL)-4-PHENYL-5-T) is a potent and highly selective inhibitor of COX-2 and COX-1. It is also a potent inhibitor of PKB Akt and MAPK signalling pathways and induces apoptosis in NSC-LC cells, with analgesic, anti-inflammatory and anti-cancer activities.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
AKT-IN-2
T102741295514-91-8
AKT-IN-2 is a selective, and orally bioavailable AKT inhibitor (IC50: 5 nM for AKT1).
  • Inquiry Price
6-8 weeks
Size
QTY
VEGFR-2/AKT-IN-2
T203454
VEGFR-2 AKT-IN-2 (Compound 5) is an inhibitor of VEGFR-2 AKT, with an IC50 of 0.061 μM for VEGFR in human liver cancer cells. It reduces total and phosphorylated AKT in cells, increases BAX and caspase-3 levels, and decreases Bcl-2, thereby inducing apoptosis. Additionally, VEGFR-2 AKT-IN-2 halts the cell cycle at the S phase and inhibits the growth of human liver cancer cells.
  • Inquiry Price
Size
QTY
SC66
T3132871361-88-5
SC66 is a AKT inhibitor in HepG2, HA22T VGH, and PLC PRF 5 cells (IC50: about 0.75 μg ml, at 72 h).
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
2-Amino-5-bromo-6-chloropyrazine
T35490173253-42-4
2-Amino-5-bromo-6-chloropyrazine is a heterocyclic building block.1,2It has been used in the synthesis of Akt inhibitors. 1.Kettle, J.G., Brown, S., Crafter, C., et al.Diverse heterocyclic scaffolds as allosteric inhibitors of AKTJ. Med. Chem.55(3)1261-1273(2012) 2.Goel, R., Luxami, V., and Paul, K.Recent advances in development of imidazo[1,2-a]pyrazines: Synthesis, reactivity and their biological applicationsOrg. Biomol. Chem.13(12)3525-3555(2015)
  • Inquiry Price
Size
QTY
AAA
T35855
AAA is an antagonist of G protein-coupled receptor 75 (GPR75).1It increases basal GPR75 protein levels and inhibits 20-HETE-induced reductions in GPR75 protein levels in PC3 cells. AAA (5 and 10 μM) also reduces 20-HETE-induced phosphorylation of EGFR, NF-κB, and Akt in, and cell migration of, PC3 cells.In vivo, AAA (10 mg/kg per day) reduces systolic blood pressure, albuminuria, renal angiotensin II levels, and cardiac hypertrophy in a Cyp1a1-Ren-2 transgenic rat model of malignant hypertension when administered prior to induction or after establishment of hypertension.2 1.Cárdenas, S., Colombero, C., Panelo, L., et al.GPR75 receptor mediates 20-HETE-signaling and metastatic features of androgen-insensitive prostate cancer cellsBiochim. Biophys. Acta Mol. Cell Biol. Lipids1865(2)158573(2020) 2.Sedláková, L., Kikerlová, S., Husková, Z., et al.20-Hydroxyeicosatetraenoic acid antagonist attenuates the development of malignant hypertension and reverses it once established: a study in Cyp1a1-Ren-2 transgenic ratsBiosci. Rep.38(5)BSR20171496(2018)
  • Inquiry Price
Size
QTY
CC260
T358742411088-26-9
CC260, a selective inhibitor for PI5P4Kα and PI5P4Kβ with Kis of 40 nM and 30 nM respectively, exhibits minimal to no inhibition against other protein kinases like Plk1 and RSK2. It is applicable in the research of cell energy metabolism, diabetes, and cancer[1].
  • Inquiry Price
6-8 weeks
Size
QTY
CAY10747
T361972413849-81-5
CAY10747 is an inhibitor of the protein-protein interaction between heat shock protein 90 (Hsp90) and cell division cycle 37 (Cdc37) and a derivative of celastrol .1It decreases protein levels of the Hsp90-Cdc37 complex and the Hsp90-Cdc37 clients phosphorylated Akt and Cdk4 in A549 cells when used at a concentration of 5 μM. CAY10747 inhibits proliferation of A549, MCF-7, HOS, and HepG2 cells (IC50s = 0.41, 0.64, 0.9, and 0.94 μM, respectively) and induces apoptosis in A549 cells. 1.Li, N., Xu, M., Wang, B., et al.Discovery of novel celastrol derivatives as Hsp90-Cdc37 interaction disruptors with antitumor activityJ. Med. Chem.62(23)10798-10815(2019)
  • Inquiry Price
6-8 weeks
Size
QTY
MMP-9-IN-5
T640832581824-80-6
MMP-9-IN-5 is an MMP-9 inhibitor with an IC50 value of 4.49 nM and is able to form hydrogen bonds with MMP-9. MMP-9-IN-5 also inhibits AKT activity with an IC50 value of 1.34 nM. MMP-9-IN-5 exhibits cytotoxicity, induces apoptosis and can be used in cancer research.
  • Inquiry Price
6-8 weeks
Size
QTY
Rhynchophylline
Rhyncophylline, Rhynchophyllin, Mitrinermine, Mitrinermin
T6S065976-66-4
1. Rhynchophylline (Mitrinermine) can protect against ischemic damage, probably via regulating the Akt mTOR pathway. 2. Rhynchophylline can protect against glutamate-induced neuronal death, can inhibit MA impairment in cultured neurons in vitro. 3. Rhynchophylline and isorhynchophylline have a non-competitive antagonistic effect on the NMDA-type ionotropic glutamate receptors, suggest that these alkaloids exert their protective action against ischemia-induced neuronal damage by preventing NMDA, muscarinic M1, and 5-HT2 receptors-mediated neurotoxicity during ischemia.
  • Inquiry Price
Size
QTY
Geraniin
T6S209960976-49-0
1. Geraniin has a protective effect against OVX-induced rat osteoporosis. 2. Geraniin has cytotoxic activity towards cancer cells in vitro and in vivo. 3. Geraniin exerts inhibitory effects on osteoclast differentiation in vitro and suppresses Ti particle
  • Inquiry Price
Size
QTY
2-Chlorophenoxazine
T7972256821-03-5
2-Chlorophenoxazine is an Akt inhibitor that demonstrates an in vitro inhibitory concentration (IC50) of 2-5 μM and has the capacity to induce apoptosis. It is utilized in the research of cancer diseases [1].
  • Inquiry Price
8-10 weeks
Size
QTY
N-Arachidonoyl-L-Serine
ARA-S
T84551187224-29-9
N-Arachidonoyl-L-serine (ARA-S), a recently isolated endocannabinoid with a distinct activity profile that diverges from typical endocannabinoids, does not interact with central cannabinoid (CB1), peripheral cannabinoid (CB2) receptors, or vanilloid receptor 1 (VR1). Unlike other compounds, ARA-S (5 mg/kg) counteracts the lowering of blood pressure induced by a 10 mg/kg intravenous bolus of abnormal cannabidiol (Abn-CBD) in anesthetized rat models. Additionally, akin to Abn-CBD, ARA-S induces relaxation in isolated rat mesenteric arteries and abdominal aorta and promotes phosphorylation of Akt and mitogen-activated protein kinase (MAPK) in human umbilical vein endothelial cells (HUVEC). The mechanisms through which ARA-S and Abn-CBD exert their effects on vascular systems show variations and merit deeper investigation.
  • Inquiry Price
8-10 weeks
Size
QTY
QLT0267
T84998866409-68-9
QLT0267 is an inhibitor targeting integrin-linked kinase (ILK; IC50= 26 nM), showing over 10-fold selectivity against cyclin-dependent kinases 1, 2, and 5 (Cdk1, Cdk2, and Cdk5), and over 1,000-fold selectivity against C-terminal Src kinase (CSK), DNA-PK, Pim-1, Akt, PKC, and casein kinase 2 (CK2) at a concentration of 10 mg/ml. This compound effectively inhibits the proliferation of NPA187 papillary thyroid cancer cells with an IC50 of approximately 3 µM and induces apoptosis in NPA187, DRO, and K4 cancer cell lines. In vivo studies reveal that QLT0267, administered at 100 mg/kg, significantly reduces tumor growth in a DRO mouse xenograft model and diminishes both tumor volume and intratumoral vascularization in a U87MG glioblastoma mouse xenograft model, showcasing its potential for therapeutic applications in cancer treatment.
  • Inquiry Price
35 days
Size
QTY